Compare Immunovant Inc. Common Stock (IMVT) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Moody's Corporation — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Moody's Corporation trades at $458.77 (market cap $77.87B). The key difference: Moody's Corporation is far larger — about 11.8× Immunovant Inc. Common Stock's market cap, and Moody's Corporation pays a 0.92% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Moody's Corporation for 132 Days on average.
| IMVT | MCO | |
|---|---|---|
Market Cap | $6.62B | $77.87B |
Volume | 1,131,364 | 633,412 |
Sector | Health | Financials |
52-Week High | $44.96 | $539.61 |
52-Week Low | $17.03 | $412.23 |
Typical Hold Time | 0 Days | 132 Days |
Enterprise Value | $5.72B | $83.89B |
Dividend Yield | — | 0.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moody's Corporation (MCO) trades at $458.69, up 1.41% with strong fundamentals including 34.25% net income margin and 80.15% ROE. The stock shows bearish technical signals but has consistently beaten earnings estimates in recent quarters. Recent developments include a minority stake acquisition in Philippine Rating Services and continued leadership in risk analytics, with the company ranking #1 in Chartis RiskTech100 for the fifth consecutive year.
Despite technical weakness, Moody's maintains strong profitability and analyst support with 56% buy ratings and a $536.40 consensus target. Key risks include high valuation multiples and potential market volatility, but the company's dominant market position and consistent earnings growth support long-term investment appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
